"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,ES,T3,ES 2417488 T3,049-938-051-308-378,2013-08-08,2013,ES 05823049 T,2005-12-01,US 63241204 P;;EP 2005012856 W,2004-12-02,Compuestos de triazol adecuados para tratar trastornos que responden a la modulación del receptor de dopamina D3,"Compuestos de triazol de fórmula I en la que n es 1 ó 2, Ar es un radical 1, 2, 4-triazol unido a C que porta un radical R1 en el átomo de carbono restante y un radical R1a en uno de los átomos de nitrógeno; R1 es hidrógeno, alquilo C1-C6, cicloalquilo C3-C6, alcoximetilo C1-C4, alquilo C1-C6 fluorado, cicloalquilo C3-C6 fluorado, alcoximetilo C1-C4 fluorado, fenilo o heteroarilo de 5 ó 6 miembros, pudiendo estar fenilo y heteroarilo sustituidos o no sustituidos por 1, 2, 3 ó 4 radicales Ra seleccionados independientemente entre sí de halógeno, 10 alquilo C1-C6, cicloalquilo C3-C6, alcoxi C1-C4-alquilo C1-C4, alquilo C1-C4 fluorado, CN, NO2, OR3, NR3R4, C (O) NR3R4, O-C (O) NR3R4, SO2NR3R4, COOR5, SR6, SOR6, SO2R6, O-C (O) R7, COR7 o cicloalquilmetilo C3-C5, pudiendo portar también fenilo y heteroarilo un grupo fenilo o un radical heteroaromático unido a C, aromático de 5 ó 6 miembros, que comprende 1 átomo de nitrógeno como miembro del anillo y 0, 1, 2 ó 3 heteroátomos adicionales, independientemente entre sí, seleccionados de O, S y N, pudiendo portar al menos dos radicales mencionados 1, 2, 3 ó 4 de los radicales Ra mencionados anteriormente, R1a es hidrógeno o alquilo C1-C4, R2 es alquilo C1-C6, cicloalquilo C3-C6, alquilo C1-C6 fluorado o cicloalquilo C3-C6 fluorado, R3, R4, R5, R6 y R7 independientemente entre sí son H, alquilo C1-C6, opcionalmente sustituido con OH, alcoxilo C1-C4 o fenilo, haloalquilo C1-C4 o fenilo, que puede portar 1, 2 ó 3 radicales seleccionados del grupo que consiste en 20 alquilo C1-C6, alcoxilo C1-C6, NR3aR4a, CN, fluoroalquilo C1-C2 y halógeno, siendo R3a y R4a independientemente entre sí, H, alquilo C1-C6, opcionalmente sustituido con OH, alcoxilo C1-C4 o fenilo, haloalquilo C1-C4 o fenilo, que puede portar 1, 2 ó 3 radicales seleccionados del grupo que consiste en alquilo C1-C6, alcoxilo C1-C6, amino, NH (alquilo C1-C4) y N (alquilo C1-C4) 2, R4 también puede ser un radical COR8, siendo R8 hidrógeno, alquilo C1-C6, alcoxilo C1-C6 o fenilo, que puede portar 1, 2 ó 3 radicales seleccionados del grupo que consiste en alquilo C1-C6, alcoxilo C1-C6, NR3R4, CN, fluoroalquilo C1-C2 y halógeno, R3 y R4 pueden formar, junto con el átomo de nitrógeno al que están unidos, un heterociclo saturado de 5 ó 6 miembros unido a N, que puede comprender un átomo de oxígeno o un átomo de nitrógeno adicional como miembro del anillo y que puede portar 1, 2, 3 ó 4 grupos alquilo C1-C6, y las sales de adición de ácido fisiológicamente toleradas de estos compuestos.",ABBOTT GMBH & CO KG,UNGER LILIANE;;HAUPT ANDREAS;;BEYERBACH ARMIN;;DRESCHER KARLA;;BRAJE WILFRIED;;DARBYSHIRE JOHN;;TURNER SEAN;;BACKFISCH GISELA,,https://lens.org/049-938-051-308-378,Granted Patent,no,0,0,18,18,0,C07D403/12;;A61P13/12;;A61P15/08;;A61P15/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/00;;A61P3/10;;A61P43/00;;C07D401/04;;C07D401/14;;C07D403/12,A61K31/506;;A61P25/18;;C07D403/12,,0,0,,,,ACTIVE
2,AU,A1,AU 2005/311452 A1,041-952-300-931-356,2006-06-08,2006,AU 2005/311452 A,2005-12-01,US 63241204 P;;EP 2005012856 W,2004-12-02,Triazole compounds suitable for treating disorders that respond to modulaiont of the dopamine D3 receptor,,ABBOTT GMBH & CO KG,TURNER SEAN C;;HAUPT ANDREAS;;DARBYSHIRE JOHN;;DRESCHER KARLA;;BACKFISCH GISELA;;UNGER LILIANE;;BEYERBACH ARMIN;;BRAJE WILFRIED,,https://lens.org/041-952-300-931-356,Patent Application,no,0,0,18,18,0,C07D403/12;;A61P13/12;;A61P15/08;;A61P15/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/00;;A61P3/10;;A61P43/00;;C07D401/04;;C07D401/14;;C07D403/12,A61K31/506;;A61P25/18;;C07D403/12,,0,0,,,,DISCONTINUED
3,WO,A1,WO 2006/058753 A1,076-418-167-183-167,2006-06-08,2006,EP 2005012856 W,2005-12-01,US 63241204 P,2004-12-02,TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULAIONT OF THE DOPAMINE D3 RECEPTOR,"The invention relates to compounds of formula (I), wherein n is 1 or 2, Ar is a C-bound 1,2,4-triazol radical which carries a radical R1 on the remaining carbon atom and a radical R1a on one of the nitrogen atoms; R1 is hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C4 alkoxymethyl, fluorinated C1-C6 alkyl, fluorinated C3-C6 cycloalkyl, fluorinated C1-C4 alkoxymethyl, or optionally substituted phenyl or 5- or 6-membered heteroaryl; R1a is hydrogen or C1-C4 alkyl; and R2 is C1-C6 alkyl, C3-C6 cycloalkyl, fluorinated C1-C6 alkyl or fluorinated C3-C6 cycloalkyl; and to the physiologically tolerated acid addition salts of there compounds. The invention also relates to a pharmaceuticaly composition that comprises at least one triazole compound of the formula (I) and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said method comprising administering an effective amount of at least one traizole compound or physiologically tolerated acid addition salt of the formula (I) to a subject in need thereof.",ABBOTT GMBH & CO KG;;UNGER LILIANE;;HAUPT ANDREAS;;BEYERBACH ARMIN;;DRESCHER KARLA;;BRAJE WILFRIED;;DARBYSHIRE JOHN;;TURNER SEAN C;;BACKFISCH GISELA,UNGER LILIANE;;HAUPT ANDREAS;;BEYERBACH ARMIN;;DRESCHER KARLA;;BRAJE WILFRIED;;DARBYSHIRE JOHN;;TURNER SEAN C;;BACKFISCH GISELA,,https://lens.org/076-418-167-183-167,Patent Application,yes,4,8,18,18,0,C07D403/12;;A61P13/12;;A61P15/08;;A61P15/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/00;;A61P3/10;;A61P43/00;;C07D401/04;;C07D401/14;;C07D403/12,A61K31/506;;A61P25/18;;C07D403/12,,0,0,,,,PENDING
4,US,B2,US 11574876 B2,187-824-473-381-186,2023-02-07,2023,US 201816008961 A,2018-06-14,US 201816008961 A;;US 201213652194 A,2012-10-15,Microchip charge patterning,"A method of forming a charge pattern on a microchip includes depositing a material on the surface of the microchip, and immersing the microchip in a fluid to develop charge in or on the material through interaction with the surrounding fluid.",PALO ALTO RES CT INC,CHOW EUGENE M;;LU JENPING;;VOLKEL ARMIN R;;HSIEH BING R;;WHITING GREGORY L;;DORIS SEAN E,PALO ALTO RESEARCH CENTER INCORPORATED (2018-06-11);;XEROX CORPORATION (2023-04-16),https://lens.org/187-824-473-381-186,Granted Patent,yes,18,0,8,8,0,H01L24/95;;H01L2223/5442;;H01L2223/54426;;H01L2223/54433;;H01L2224/95085;;H01L2224/95145;;H01L2924/10253;;H01L2924/10329;;H01L23/544;;H01L24/95;;H01L2223/5442;;H01L2223/54426;;H01L2223/54433;;H01L2224/95085;;H01L2224/95145;;H01L2924/10253;;H01L2924/10329;;H01L23/544,H01L21/00;;H01L23/00;;H01L23/544,,4,2,086-995-860-001-053;;097-202-785-873-199,10.1021/cr040087x;;17091929;;23402544;;10.1021/la3049086,"Detig, Robert H., “Electrophorectic Self Assembly: A Manufacturing Process for Various Industries,” Final Program and Proceedings of IS&T's NIP20: International Conference on Digital Printing Technologies, Oct. 31-Nov. 5, 2004, Salt Lake City, UT, Society for Imaging Science and Technology, Oct. 31, 2004, pp. 236-240.;;European Search Report, EP 13 18 8461, dated Feb. 28, 2014, 9 pages.;;Marcus et al., “Ion Pairing,” Chem. Rev. 2006, 106, 4585-4621.;;Hussain et al., “Charge Generation in Low-Polarity Solvents: Poly(ionic liquid)-Functionalized Particles,” Langmuir (2013), 29, 4204-4213.",ACTIVE
5,TW,A,TW 200633710 A,108-960-356-952-665,2006-10-01,2006,TW 94142668 A,2005-12-02,US 63241204 P,2004-12-02,Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor,"The invention relates to compounds of the formula I: wherein n is 1 or 2, Ar is a C-bound 1,2,4-triazol radical which carries a radical R1 on the remaining carbon atom and a radical R1a on one of the nitrogen atoms; R1 is hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C4 alkoxymethyl, fluorinated C1-C6 alkyl, fluorinated C3-C6 cycloalkyl, fluorinated C1-C4 alkoxymethyl, or optionially substituted phenyl or 5- or 6-membered heteroaryl; R1a is hydrogen or C1-C4 alkyl; and R2 is C1-C6 alkyl, C3-C6 cycloalkyl, fluorinated C1-C6 alkyl or fluorinated C3-C6 cycloalkyl; and to the physiologically tolerated acid addition salts of these compounds. The invention also relates to a pharmaceutical composition that comprises at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.",ABBOTT GMBH & CO KG,HAUPT ANDREAS;;BRAJE WILFRIED;;DRESCHER KARLA;;UNGER LILIANE;;BEYERBACH ARMIN;;DARBYSHIRE JOHN;;BACKFISCH GISELA;;TURNER SEAN C,,https://lens.org/108-960-356-952-665,Patent of Addition,no,0,0,18,18,0,C07D403/12;;A61P13/12;;A61P15/08;;A61P15/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/00;;A61P3/10;;A61P43/00;;C07D401/04;;C07D401/14;;C07D403/12,,,0,0,,,,PENDING
6,CA,A1,CA 2588457 A1,091-675-698-674-804,2006-06-08,2006,CA 2588457 A,2005-12-01,US 63241204 P;;EP 2005012856 W,2004-12-02,TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR,,ABBOTT GMBH & CO KG,TURNER SEAN C;;BACKFISCH GISELA;;DARBYSHIRE JOHN;;UNGER LILIANE;;HAUPT ANDREAS;;DRESCHER KARLA;;BEYERBACH ARMIN;;BRAJE WILFRIED,,https://lens.org/091-675-698-674-804,Patent Application,no,0,0,18,18,0,C07D403/12;;A61P13/12;;A61P15/08;;A61P15/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/00;;A61P3/10;;A61P43/00;;C07D401/04;;C07D401/14;;C07D403/12,A61P25/18;;A61K31/506;;C07D403/12,,0,0,,,,DISCONTINUED
7,US,A1,US 2012/0095015 A1,089-075-132-712-110,2012-04-19,2012,US 201113333702 A,2011-12-21,US 201113333702 A;;US 79259608 A;;EP 2005012856 W;;US 63241204 P,2004-12-02,TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR,"The invention relates to compounds of formula (I), wherein n is 1 or 2, Ar is a C-bound 1,2,4-triazol radical which carries a radical R 1 on the remaining carbon atom and a radical R 1a on one of the nitrogen atoms; R 1 is hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 alkoxymethyl, fluorinated C 1 -C 6 alkyl, fluorinated C 3 -C 6 cycloalkyl, fluorinated C 1 -C 4 alkoxymethyl, or optionally substituted phenyl or 5- or 6-membered heteroaryl; R 1a is hydrogen or C 1 -C 4 alkyl; and R 2 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, fluorinated C 1 -C 6 alkyl or fluorinated C 3 -C 6 cycloalkyl; and to the physiologically tolerated acid addition salts of there compounds. The invention also relates to a pharmaceutically composition that comprises at least one triazole compound of the formula (I) and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula (I) to a subject in need thereof.",UNGER LILIANE;;HAUPT ANDREAS;;BEYERBACH ARMIN;;DRESCHER KARLA;;BRAJE WILFRIED;;DARBYSHIRE JOHN;;TURNER SEAN C;;BACKFISCH GISELA,UNGER LILIANE;;HAUPT ANDREAS;;BEYERBACH ARMIN;;DRESCHER KARLA;;BRAJE WILFRIED;;DARBYSHIRE JOHN;;TURNER SEAN C;;BACKFISCH GISELA,ABBVIE DEUTSCHLAND GMBH & CO KG (2012-11-01),https://lens.org/089-075-132-712-110,Patent Application,yes,5,0,18,18,0,C07D403/12;;A61P13/12;;A61P15/08;;A61P15/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/00;;A61P3/10;;A61P43/00;;C07D401/04;;C07D401/14;;C07D403/12,A61K31/506;;A61P25/00;;A61P25/18;;C07D403/14,514/252.19;;544/295,0,0,,,,DISCONTINUED
8,US,A1,US 2023/0187373 A1,171-829-612-003-292,2023-06-15,2023,US 202318164070 A,2023-02-03,US 202318164070 A;;US 201816008961 A;;US 201213652194 A,2012-10-15,MICROCHIP CHARGE PATTERNING,"A method of forming a charge pattern on a microchip includes depositing a first material on an insulator surface of the microchip, depositing a material having capability of forming a self-assembled monolayer on the other material, wherein the material comprises at least one material selected from the group consisting of: octadecyltrichlorosilane, phenethyltrichlorosilane, hexamethyldisilazane, allyltrimethoxysilane, or perfluorooctyltrichlorosilanem, and patterning the self-assembled monolayer to reveal a portion of the first material. A method of forming a charge pattern in a microchip includes depositing a first material as one of either a solution processed material or a vapor deposited material to generate a first polarity or first magnitude of charge, depositing a second material as a vapor deposited material to generate a second polarity or second magnitude of charge, and immersing the microchip in a non-polar fluid comprising one selected from the group consisting of: an isoparafinnic liquid, a hydrocarbon liquid and dodecane.",PALO ALTO RES CT INC,CHOW EUGENE M;;LU JENPING;;VOLKEL ARMIN R;;HSIEH BING R;;WHITING GREGORY L;;DORIS SEAN E,PALO ALTO RESEARCH CENTER INCORPORATED (2012-10-08);;XEROX CORPORATION (2023-04-16),https://lens.org/171-829-612-003-292,Patent Application,yes,2,0,8,8,0,H01L24/95;;H01L2223/5442;;H01L2223/54426;;H01L2223/54433;;H01L2224/95085;;H01L2224/95145;;H01L2924/10253;;H01L2924/10329;;H01L23/544;;H01L24/95;;H01L2223/5442;;H01L2223/54426;;H01L2223/54433;;H01L2224/95085;;H01L2224/95145;;H01L2924/10253;;H01L2924/10329;;H01L23/544,H01L23/544;;H01L23/00,,0,0,,,,PENDING
9,US,A1,US 2018/0294232 A1,033-259-371-411-790,2018-10-11,2018,US 201816008961 A,2018-06-14,US 201816008961 A;;US 201213652194 A,2012-10-15,MICROCHIP CHARGE PATTERNING,"A method of forming a charge pattern on a microchip includes depositing a material on the surface of the microchip, and immersing the microchip in a fluid to develop charge in or on the material through interaction with the surrounding fluid.",PALO ALTO RES CT INC,CHOW EUGENE M;;LU JENPING;;VOLKEL ARMIN R;;HSIEH BING R;;WHITING GREGORY L;;DORIS SEAN E,PALO ALTO RESEARCH CENTER INCORPORATED (2018-06-11);;XEROX CORPORATION (2023-04-16),https://lens.org/033-259-371-411-790,Patent Application,yes,19,0,8,8,0,H01L24/95;;H01L2223/5442;;H01L2223/54426;;H01L2223/54433;;H01L2224/95085;;H01L2224/95145;;H01L2924/10253;;H01L2924/10329;;H01L23/544;;H01L24/95;;H01L2223/5442;;H01L2223/54426;;H01L2223/54433;;H01L2224/95085;;H01L2224/95145;;H01L2924/10253;;H01L2924/10329;;H01L23/544,H01L23/544;;H01L23/00,,3,2,086-995-860-001-053;;097-202-785-873-199,10.1021/cr040087x;;17091929;;23402544;;10.1021/la3049086,"DETIG ROBERT H.: ""Electrophorectic Self Assembly : A Manufacturing Process for various Industries"", FINAL PROGRAM AND PROCEEDINGS OF IS&T'S NIP20 : INTERNATIONAL CONFERENCE ON DIGITAL PRINTING TECHNOLOGIES, 31 October 2004 (2004-10-31), Salt Lake City, UT, Society for Imaging Science and Technology, pages 236 - 240, XP009176344;;MARCUS ET AL.: ""Ion pairing"", CHEM REV, vol. 106, 2006, pages 4585 - 4621;;HUSSAIN ET AL.: ""Charge generation in Low-Polarity Solvents: Poly(ionic liquid)- Functionalized particles"", LANGMUIR, vol. 29, 2013, pages 4204 - 4213",ACTIVE
10,US,B2,US 8101754 B2,091-426-540-706-936,2012-01-24,2012,US 79259605 A,2005-12-01,US 79259605 A;;US 63241204 P;;EP 2005012856 W,2004-12-02,Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor,"The invention relates to compounds of the formula I: wherein n is 1 or 2,Ar is a C-bound 1,2,4-triazol radical which carries a radical R 1 on the remaining carbon atom and a radical R 1a on one of the nitrogen atoms;R 1 is hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 alkoxymethyl, fluorinated C 1 -C 6 alkyl, fluorinated C 3 -C 6 cycloalkyl, fluorinated C 1 -C 4 alkoxymethyl, or optionially substituted phenyl or 5- or 6-membered heteroaryl;R 1a is hydrogen or C 1 -C 4 alkyl; andR 2 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, fluorinated C 1 -C 6 alkyl or fluorinated C 3 -C 6 cycloalkyl; and to the physiologically tolerated acid addition salts of these compounds. The invention also relates to a pharmaceutical composition that comprises at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.",UNGER LILIANE;;HAUPT ANDREAS;;BEYERBACH ARMIN;;DRESCHER KARLA;;BRAJE WILFRIED;;DARBYSHIRE JOHN;;TURNER SEAN C;;BACKFISCH GISELA;;ABBOTT GMBH & CO KG,UNGER LILIANE;;HAUPT ANDREAS;;BEYERBACH ARMIN;;DRESCHER KARLA;;BRAJE WILFRIED;;DARBYSHIRE JOHN;;TURNER SEAN C;;BACKFISCH GISELA,ABBOTT GMBH & CO. KG (2007-07-31);;ABBVIE DEUTSCHLAND GMBH & CO KG (2012-11-01),https://lens.org/091-426-540-706-936,Granted Patent,yes,12,1,18,18,0,C07D403/12;;A61P13/12;;A61P15/08;;A61P15/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/00;;A61P3/10;;A61P43/00;;C07D401/04;;C07D401/14;;C07D403/12,A61K31/506;;C07D403/14;;A61P25/18;;C07D403/12,544/327;;514/252.19,7,5,096-583-800-197-72X;;045-186-931-440-022;;031-458-967-384-69X;;085-016-098-817-131;;066-203-166-874-90X,10.1016/j.tips.2008.03.009;;18471899;;10.1016/s1359-6446(05)03491-4;;15993811;;9638397;;10.2165/00002512-199812060-00007;;10.1016/s0163-7258(01)00139-5;;11578658;;10.1038/347146a0;;1975644,"Strange, PG., et al., Trends in Pharmacological Sciences, vol. 29, No. 6, 314-321, 2008.;;Joyce et al., Drug Discovery Today, vol. 10, No. 13, 917-925, 2005.;;J.C. Schwartz et al., The Dopamine D3 Receptor as a Target for Antipsychotics, in Novel Antipsychotic Drugs, H.Y. Meltzer, Ed. Raven Press, New York, 1992, pp. 135-144.;;M. Dooley et al., ""Pramipexole, A Review of its Use in the Management of Early and Advanced Parkinson's Disease""; Drugs and Aging 1998, 12, 495-514.;;J. N. Joyce, Pharmacology and Therapeutics 2001, 90, pp. 231-259 ""The Dopamine D3 Receptor as a Therapeutic Target for Antipsychotic and Antiparkinsonian Drugs"".;;P. Sokoloff et al., Localization and Function of the D3 Dopamine Receptor, Arzneim. Frosch./Drug Res. 42(1), 224 (1992).;;P. Sokoloff et al., Molecular Cloning and Characterization of a Novel Dopamine Receptor (D3) as a Target for Neuroleptics, Nature, 347, 146 (1990).",INACTIVE
11,EP,B1,EP 1817037 B1,171-729-411-144-816,2013-04-03,2013,EP 05823049 A,2005-12-01,EP 2005012856 W;;US 63241204 P,2004-12-02,TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR,,ABBOTT GMBH & CO KG,UNGER LILIANE;;HAUPT ANDREAS;;BEYERBACH ARMIN;;DRESCHER KARLA;;BRAJE WILFRIED;;DARBYSHIRE JOHN;;TURNER SEAN C;;BACKFISCH GISELA,ABBVIE DEUTSCHLAND GMBH & CO KG (2013-10-16),https://lens.org/171-729-411-144-816,Granted Patent,yes,4,0,18,18,0,C07D403/12;;A61P13/12;;A61P15/08;;A61P15/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/00;;A61P3/10;;A61P43/00;;C07D401/04;;C07D401/14;;C07D403/12,A61K31/506;;A61P25/18;;C07D403/12,,0,0,,,,ACTIVE
12,ZA,B,ZA 200705008 B,182-690-410-111-67X,2008-09-25,2008,ZA 200705008 A,2007-06-01,US 63241204 P,2004-12-02,Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor,,ABBOTT GMBH & CO KG,LILIANE UNGER;;ARMIN BEYERBACH;;WILFRIED BRAJE;;TURNER SEAN C;;ANDREAS HAUPT;;KARLA DRESCHER;;JOHN DARBYSHIRE;;GISELA BACKFISCH,,https://lens.org/182-690-410-111-67X,Granted Patent,no,0,0,18,18,0,C07D403/12;;A61P13/12;;A61P15/08;;A61P15/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/00;;A61P3/10;;A61P43/00;;C07D401/04;;C07D401/14;;C07D403/12,A61K/;;A61P/;;C07D/,,0,0,,,,ACTIVE
13,US,A1,US 2008/0171751 A1,197-743-807-734-534,2008-07-17,2008,US 79259605 A,2005-12-01,US 79259605 A;;US 63241204 P;;EP 2005012856 W,2004-12-02,Triazole Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor,"The invention relates to compounds of the formula I: wherein n is 1 or 2,Ar is a C-bound 1,2,4-triazol radical which carries a radical R 1 on the remaining carbon atom and a radical R 1a on one of the nitrogen atoms;R 1 is hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 alkoxymethyl, fluorinated C 1 -C 6 alkyl, fluorinated C 3 -C 6 cycloalkyl, fluorinated C 1 -C 4 alkoxymethyl, or optionally substituted phenyl or 5- or 6-membered heteroaryl;R 1a is hydrogen or C 1 -C 4 alkyl; andR 2 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, fluorinated C 1 -C 6 alkyl or fluorinated C 3 -C 6 cycloalkyl; and to the physiologically tolerated acid addition salts of these compounds. The invention also relates to a pharmaceutical composition that comprises at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.",UNGER LILIANE;;HAUPT ANDREAS;;BEYERBACH ARMIN;;DRESCHER KARLA;;BRAJE WILFRIED;;DARBYSHIRE JOHN;;TURNER SEAN C;;BACKFISCH GISELA,UNGER LILIANE;;HAUPT ANDREAS;;BEYERBACH ARMIN;;DRESCHER KARLA;;BRAJE WILFRIED;;DARBYSHIRE JOHN;;TURNER SEAN C;;BACKFISCH GISELA,ABBOTT GMBH & CO. KG (2007-07-31);;ABBVIE DEUTSCHLAND GMBH & CO KG (2012-11-01),https://lens.org/197-743-807-734-534,Patent Application,yes,4,4,18,18,0,C07D403/12;;A61P13/12;;A61P15/08;;A61P15/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/00;;A61P3/10;;A61P43/00;;C07D401/04;;C07D401/14;;C07D403/12,A61K31/496;;A61P25/00;;C07D403/14,514/252.19;;544/333,0,0,,,,INACTIVE
14,MX,A,MX 2007006598 A,003-739-463-391-04X,2007-09-21,2007,MX 2007006598 A,2005-12-01,US 63241204 P;;EP 2005012856 W,2004-12-02,TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULAIONT OF THE DOPAMINE D3 RECEPTOR.,"The invention relates to compounds of formula (I), wherein n is 1 or 2, Ar is a C-bound 1,2,4-triazol radical which carries a radical R<sup>1</sup> on the remaining carbon atom and a radical R<sup>1a</sup> on one of the nitrogen atoms; R<sup>1</sup> is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxymethyl, fluorinated C<sub>1</sub>-C<sub>6</sub> alkyl, fluorinated C<sub>3</sub>-C<sub>6</sub> cycloalkyl, fluorinated C<sub>1</sub>-C<sub>4</sub> alkoxymethyl, or optionally substituted phenyl or 5- or 6-membered heteroaryl; R<sup>1a</sup> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl; and R<sup>2</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, fluorinated C<sub>1</sub>-C<sub>6</sub> alkyl or fluorinated C<sub>3</sub>-C<sub>6</sub> cycloalkyl; and to the physiologically tolerated acid addition salts of there compounds. The invention also relates to a pharmaceuticaly composition that comprises at least one triazole compound of the formula (I) and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D<sub>3</sub> receptor antagonists or dopamine D<sub>3</sub> agonists, said method comprising administering an effective amount of at least one traizole compound or physiologically tolerated acid addition salt of the formula (I) to a subject in need thereof.",ABBOTT GMBH & CO KG,TURNER SEAN C;;UNGER LILIANE;;DRESCHER KARLA;;HAUPT ANDREAS;;BRAJE WILFRIED;;BEYERBACH ARMIN;;DARBYSHIRE JOHN;;BACKFISCH GISELA,,https://lens.org/003-739-463-391-04X,Patent Application,no,0,0,18,18,0,C07D403/12;;A61P13/12;;A61P15/08;;A61P15/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/00;;A61P3/10;;A61P43/00;;C07D401/04;;C07D401/14;;C07D403/12,C07D403/12;;A61K31/00;;A61P25/18,,0,0,,,,DISCONTINUED
15,BR,A2,BR PI0518823 A2,020-049-177-338-094,2008-12-09,2008,BR PI0518823 A,2005-12-01,US 63241204 P;;EP 2005012856 W,2004-12-02,compostos de triazol adequados para o tratamento de transtornos que respondam À modulaÇço do receptor d3 da dopamina,"COMPOSTOS DE TRIAZOL ADEQUADOS PARA O TRATAMENTO DE TRANSTORNOS QUE RESPONDAM A MODULAÇçO DO RECEPTOR D~ 3~ DA DOPAMINA. A invencão se refere a compostos de fórmula (I) em que n é 1 ou 2, Ar é um radical 1,2,4-triazol ligado a C que possui um radical R¹ no átomo de carbono restante e um radical R^ 1a^ em s átomos de nitrogênio; R¹ é hidrogênio, um do C~ 1~-C~ 6~ alquila, C~ 3~ - C~ 6~ cicloalquila, C~ 1~ - C~ 4~ alcoximetila, C~ 1~ - C~ 6~ alquila fluorada, C~ 3~ - C~ 6~ cicloalquila fluorada, C~ 1~ - C~ 4~ alcoximetila fluorada ou fenila ou heteroarila de 5 ou 6 elementos opcionalmente substituida; R^ 1a^ é hidrogênio ou C~ 1~ - C~ 4~ alquila; e R² e C~ 1~ - C~ 6~ alquila, C~ 3~ - C~ 6~ cicloalquila, C~ 1~ - C~ 6~ alquila fluorada ou C~ 3~ - C~ 6~ cicloalquila fluorada; e aos sais de adição de ácido fisiologicamente tolerados desses compostos. A invenção também se refere a uma composiçâo farmacêutica que compreenda pelo menos um composto de triazol de fórmula (I) e/ou pelo menos um sal de adição de ácido fisiologicamente tolerado dele, e também a um método para o tratamento de transtornos que respondam beneficamente a antagonistas do receptor D~ 3~ de dopamina ou agonistas de D~ 3~ de dopamina, o dito método compreendendo a administração de uma quantidade eficaz de pelo menos um composto de triazol ou sal de adição de ácido fisiologicamente tolerado de fórmula (I) a um sujeito necessitado.",ABBOTT GMBH & CO KG,HAUPT ANDREAS;;BRAJE WILFRIED;;DARBYSHIRE JOHN;;TURNER SEAN C;;BACKFISCH GISELA;;UNGER LILIANE;;BEYERBACH ARMIN;;DRESCHER KARLA,,https://lens.org/020-049-177-338-094,Patent Application,no,0,0,18,18,0,C07D403/12;;A61P13/12;;A61P15/08;;A61P15/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/00;;A61P3/10;;A61P43/00;;C07D401/04;;C07D401/14;;C07D403/12,A61P25/18;;A61K31/506;;C07D403/12,,0,0,,,,DISCONTINUED
16,EP,A1,EP 1817037 A1,060-685-542-683-282,2007-08-15,2007,EP 05823049 A,2005-12-01,EP 2005012856 W;;US 63241204 P,2004-12-02,TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR,,ABBOTT GMBH & CO KG,UNGER LILIANE;;HAUPT ANDREAS;;BEYERBACH ARMIN;;DRESCHER KARLA;;BRAJE WILFRIED;;DARBYSHIRE JOHN;;TURNER SEAN C;;BACKFISCH GISELA,ABBVIE DEUTSCHLAND GMBH & CO KG (2013-10-16),https://lens.org/060-685-542-683-282,Patent Application,yes,0,0,18,18,0,C07D403/12;;A61P13/12;;A61P15/08;;A61P15/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/00;;A61P3/10;;A61P43/00;;C07D401/04;;C07D401/14;;C07D403/12,A61K31/506;;A61P25/18;;C07D403/12,,0,0,,,,ACTIVE
17,KR,A,KR 20070106989 A,149-519-465-146-486,2007-11-06,2007,KR 20077015182 A,2007-07-02,US 63241204 P,2004-12-02,TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR,"The invention relates to compounds of formula (I), wherein n is 1 or 2, Ar is a C-bound 1,2,4-triazol radical which carries a radical R1 on the remaining carbon atom and a radical R1a on one of the nitrogen atoms; R1 is hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C4 alkoxymethyl, fluorinated C1-C6 alkyl, fluorinated C3-C6 cycloalkyl, fluorinated C1-C 4 alkoxymethyl, or optionally substituted phenyl or 5-or 6-membered heteroaryl; R1a is hydrogen or C1-C 4 alkyl; and R2 is C1-C6 alkyl, C3-C6 cycloalkyl, fluorinated C1-C 6 alkyl or fluorinated C3-C6 cycloalkyl; and to the physiologically tolerated acid addition salts of there compounds. The invention also relates to a pharmaceuticaly composition that comprises at least one triazole compound of the formula (I) and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said method comprising administering an effective amount of at least one traizole compound or physiologically tolerated acid addition salt of the formula (I) to a subject in need thereof.",ABBOTT GMBH & CO KG,UNGER LILIANE;;HAUPT ANDREAS;;BEYERBACH ARMIN;;DRESCHER KARLA;;BRAJE WILFRIED;;DARBYSHIRE JOHN;;TURNER SEAN C;;BACKFISCH GISELA,,https://lens.org/149-519-465-146-486,Patent Application,no,0,0,18,18,0,C07D403/12;;A61P13/12;;A61P15/08;;A61P15/10;;A61P25/00;;A61P25/08;;A61P25/14;;A61P25/16;;A61P25/18;;A61P25/20;;A61P25/22;;A61P25/24;;A61P25/26;;A61P25/28;;A61P25/30;;A61P25/32;;A61P25/34;;A61P25/36;;A61P3/00;;A61P3/10;;A61P43/00;;C07D401/04;;C07D401/14;;C07D403/12,C07D401/04;;A61P25/18;;C07D401/14,,0,0,,,,DISCONTINUED
18,AT,T1,AT E504566 T1,139-095-607-893-112,2011-04-15,2011,AT 05805167 T,2005-10-14,US 61887804 P;;EP 2005011106 W,2004-10-14,ZUR BEHANDLUNG VON AUF EINE MODULATION DES DOPAMIN-D3-REZEPTORS ANSPRECHENDE ERKRANKUNGEN GEEIGNETE HETEROCYCLISCHE VERBINDUNGEN,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED,,https://lens.org/139-095-607-893-112,Granted Patent,no,0,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,,,0,0,,,,INACTIVE
19,ES,T3,ES 2364488 T3,109-731-636-931-081,2011-09-05,2011,ES 05805167 T,2005-10-14,US 61887804 P,2004-10-14,COMPUESTOS HETEROCICLICOS ADECUADOS PARA EL TRATAMIENTO DE TRASTORNOS QUE RESPONDEN A LA MODULACION DEL RECEPTOR DE DOPAMINA.,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED,,https://lens.org/109-731-636-931-081,Granted Patent,no,0,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,C07D207/09;;A61K31/397;;A61K31/445;;A61P25/16;;C07D205/04;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14,,0,0,,,,ACTIVE
20,MX,A,MX 2007004359 A,046-240-338-291-792,2007-07-17,2007,MX 2007004359 A,2005-10-14,US 61887804 P;;EP 2005011106 W,2004-10-14,HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR.,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G isCH2 or CHR3; R1 is H, C,-C6-alkyl, C,-C6-alkylsubstituted by C3-C6-cycloalkyl, Cl-C6-hydroxyalkyl,fluorinated C,-C6-alkyl, C3-C6-cycloalkyl,fluorinated C3-C6-cycloalkyl, C3-C6 ialkenyl, fluorinated C3-C6-alkenyl, formyl, acetyl orpropionyl; R2, R3 and R4 are, independently ofeach other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl;A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene orthiophenylene, which can be substituted by one ore more substituents selectedfrom halogen, methyl, methoxy and CF3; E is NR5 or CH2,wherein R5 is H or C1 -C3-alkyl; Ar is a cyclic radicalselected from the group consisting of phenyl, a 5- or 6- imembered heteroaromaticradical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O andS and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclicor heterocyclic ring, where the heterocyclic ring comprises as r ing members1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containinggroups each independently selected from NR8, where R8 isH, C1-C4-alkyl, fluorinated C1-C4-alkyl,C1-C4 ialkylcarbonyl or fluorinated C1-C4-alkylcarbonyl,and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra, whereinthe variable Ra has the meanings given in the claims and in the description;and physiologically tolerated acid addition salts thereof. The invention alsorelates to the use of a compound of the formula I or a pharmaceutically acceptablesalt thereof for preparing a pharmaceutical composition for the treatment ofa medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,LUBISCH WILFRIED;;UNGER LILIANE;;DRESCHER KARLA;;HAUPT ANDREAS;;TURNER SEAN C;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN,,https://lens.org/046-240-338-291-792,Patent Application,no,0,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,A61K31/00;;C07D205/04;;A61P25/16;;C07D207/09;;C07D209/52;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/14,,0,0,,,,ACTIVE
21,US,B2,US 8470810 B2,041-625-927-638-454,2013-06-25,2013,US 86848010 A,2010-08-25,US 86848010 A;;US 66539907 A;;EP 2005011106 W;;US 61887804 P,2004-10-14,Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C,-C 6 -alkyl, C,-C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C,-C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 , R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one or more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN C;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED;;ABBOTT GMBH & CO KG,DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN C;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED,ABBVIE DEUTSCHLAND GMBH & CO KG (2012-11-01),https://lens.org/041-625-927-638-454,Granted Patent,yes,15,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,A61K31/397;;C07D413/02,514/210.2;;548/235,13,9,085-016-098-817-131;;067-688-210-340-740;;094-224-230-279-493;;009-976-414-319-663;;055-377-691-026-15X;;007-175-975-489-686;;031-458-967-384-69X;;085-016-098-817-131;;066-203-166-874-90X,10.1016/s0163-7258(01)00139-5;;11578658;;15619116;;10.1007/s00213-004-2096-z;;15960988;;pmc3732040;;10.1016/j.brainresrev.2004.12.033;;14506325;;10691804;;10.1046/j.1365-201x.2000.00665.x;;10.1037//0735-7044.117.1.46;;10.1037/0735-7044.117.1.46;;12619907;;9638397;;10.2165/00002512-199812060-00007;;10.1016/s0163-7258(01)00139-5;;11578658;;10.1038/347146a0;;1975644,"""Autism,"" [retrieved on Apr. 14, 2008]. Retrieved online via Internet, URL: http://www.nlm.nih.gov/medlineplus/autism.html.;;""Anxiety,"" [retrieved on Apr. 14, 2008]. Retrieved online via Internet, URL: http://www.nlm.nih.gov/medlineplus/anxiety.html.;;Joyce, J.N., Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacology and Therapeutics, 2001, 90, pp. 231-259.;;Laszy, J., et al. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology, 2005, 179, pp. 567-575.;;Heidbreder, C.A., et al., The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Research Reviews, 2005, 49, 77-105.;;Rogoz, Z., et al., Anxiolytic-like effects of preferential dopamine D3 receptor agonists in an animal model. Polish Journal of Pharmacology, 2003, 55, pp. 449-454.;;Muhlbauer, B., et al., Dopamine D3 receptors in the rat kidney: role in physiology and pathophysiology. Acta Physiologica Scandinavica, 2000, 168(1), pp. 219-223.;;Benoit, S.C., et al., Altered feeding responses in mice with targeted disruption of the dopamine-3 receptor gene. Behavioral Neuroscience, 2003, 117(1), 46-54.;;Schwartz, J.C., et al., The Dopamine D1 Receptor as a Target for Antipsychotics, in Novel Antipsychotic Drugs, H. Y. Meitzer, Ed. Raven Press, New York, 1992, pp. 135-144.;;Dooley, M, et al., Drugs and Aging, 1998, 12, pp. 495-514.;;Joyce, J.N., Pharmacology and Therapeutics, 2001, 90, pp. 231-259, ""The Dopamine D1 Receptor as a Therapeutic Target for Antipsychotic and Antiparkinsonian Drugs."";;Sokoloff, P., et al., Molecular Cloning and Characterization of a Novel Dopamine Receptor (D3) as a Target for Neuroleptics, Nature, 347, 146 (1990).;;Sokoloff, P., et al., Localization and Function of the D3 Dopamine Receptor, Arzneim, Frosch/Drug Res. 42(1), 224 (1992).",INACTIVE
22,CA,A1,CA 2583983 A1,133-368-045-862-279,2006-04-20,2006,CA 2583983 A,2005-10-14,US 61887804 P;;EP 2005011106 W,2004-10-14,HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,UNGER LILIANE;;HAUPT ANDREAS;;BEYERBACH ARMIN;;HENRY CHRISTOPHE;;BRAJE WILFRIED;;GRANDEL ROLAND;;TURNER SEAN C;;BACKFISCH GISELA;;LUBISCH WILFRIED;;DRESCHER KARLA,,https://lens.org/133-368-045-862-279,Patent Application,no,0,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,C07D207/09;;A61K31/397;;A61K31/445;;A61P25/16;;C07D205/04;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14,,0,0,,,,INACTIVE
23,BR,A,BR PI0515998 A,045-822-686-286-969,2008-08-19,2008,BR PI0515998 A,2005-10-14,US 61887804 P;;EP 2005011106 W,2004-10-14,compostos heterocìclicos adequados para tratar desordens que respondem à modulação do receptor d3 de dopamina,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN C;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED,,https://lens.org/045-822-686-286-969,Patent Application,no,0,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,C07D207/09;;C07D205/04;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14,,0,0,,,,DISCONTINUED
24,US,A1,US 2008/0045493 A1,073-211-987-171-340,2008-02-21,2008,US 66539905 A,2005-10-14,US 66539905 A;;US 61887804 P;;EP 2005011106 W,2004-10-14,Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ;R 1 is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl;R 2 , R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl;A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one or more substituents selected from halogen, methyl, methoxy and CF 3 ;E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl;Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN C;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED,DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN C;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED,ABBOTT GMBH & CO. KG (2007-06-25);;ABBVIE DEUTSCHLAND GMBH & CO KG (2012-11-01),https://lens.org/073-211-987-171-340,Patent Application,yes,2,3,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,A61K31/397;;A61K31/4025;;A61K31/4192;;A61K31/4196;;A61K31/422;;A61K31/423;;A61K31/4245;;A61K31/427;;A61K31/428;;A61K31/433;;A61K31/445;;A61K31/4523;;A61K31/496;;A61K31/4965;;A61K31/501;;A61K31/502;;A61K31/506;;A61K31/517;;A61K31/5375;;A61K31/538;;A61K31/541;;A61P25/16;;C07D205/04;;C07D207/08;;C07D211/28;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/12;;C07D409/12;;C07D411/12;;C07D413/10;;C07D413/12;;C07D413/14;;C07D417/12,514/210.2;;514/227.8;;514/237.2;;514/252.05;;514/255.05;;514/256;;514/318;;514/362;;514/363;;514/364;;514/365;;514/366;;514/372;;514/373;;514/374;;514/375;;514/378;;514/379;;514/383;;514/428;;544/122;;544/123;;544/124;;544/141;;544/238;;544/242;;544/333;;544/336;;544/405;;544/60;;546/193;;546/208;;546/209;;546/210;;546/276.4;;548/127;;548/128;;548/131;;548/134;;548/136;;548/143;;548/191;;548/214;;548/215;;548/240;;548/255;;548/266.6;;548/267.2;;548/518,0,0,,,,INACTIVE
25,EP,A1,EP 2311803 A1,148-405-708-109-021,2011-04-20,2011,EP 10183342 A,2005-10-14,EP 05805167 A;;US 61887804 P,2004-10-14,Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor,"The invention relates to compounds of the formula (I)
  
wherein 
n 
is 0, 1 or 2; 
G 
is CH 2  or CHR 3 ; 
R 1 
is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; 
R  2  R 3  and R 4 
are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; 
A 
is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; 
E 
is NR 5  or CH 2 , wherein R 5  is H or C 1 -C 3 -alkyl; 
Ar 
is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8  is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a  has the meanings given in the claims and in the description; 
 
and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN C;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED,ABBVIE DEUTSCHLAND GMBH & CO KG (2013-10-16),https://lens.org/148-405-708-109-021,Patent Application,yes,9,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,C07D207/09;;A61K31/397;;A61K31/40;;A61K31/445;;A61P25/16;;A61P25/18;;A61P25/24;;C07D205/04;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14,,84,35,031-458-967-384-69X;;085-016-098-817-131;;031-627-809-128-054;;066-203-166-874-90X;;103-874-089-842-134;;153-159-554-788-315;;053-085-428-615-638;;035-808-495-317-968;;010-087-908-931-639;;065-555-816-456-156;;078-373-504-732-902;;003-413-381-149-348;;054-835-288-313-609;;052-262-000-217-696;;036-624-218-655-088;;041-638-530-303-448;;072-395-811-410-494;;033-407-244-083-669;;088-030-824-804-950;;115-078-430-515-443;;039-499-061-311-955;;014-469-296-911-520;;021-610-971-176-86X;;003-413-381-149-348;;070-808-757-271-461;;081-850-963-221-391;;038-914-505-670-473;;007-127-643-939-955;;027-712-609-296-602;;028-842-674-934-625;;036-969-629-931-052;;045-575-040-645-410;;007-127-643-939-955;;059-901-774-892-516;;122-078-475-262-658,9638397;;10.2165/00002512-199812060-00007;;10.1016/s0163-7258(01)00139-5;;11578658;;1586393;;10.1038/347146a0;;1975644;;10.1016/s0040-4020(01)00527-0;;10.1016/s0960-894x(00)00110-4;;10782697;;11448184;;10.1021/ja010654n;;12027685;;10.1021/jo011116w;;10.1016/s0957-4166(97)00470-9;;12161153;;10.1016/s0960-894x(02)00436-5;;11859005;;10.1016/s0960-894x(02)00024-0;;10.1021/ja012610k;;12022838;;14535819;;10.1021/jo034643j;;10.1016/s0040-4020(99)00550-5;;9357535;;10.1021/jm970396y;;10.1080/00397919308009817;;10.1139/v71-498;;12361394;;10.1021/jm020124h;;10.1016/s0040-4020(02)01297-8;;10.1016/s0040-4020(01)86803-4;;10.1021/jo00245a057;;14531697;;10.1021/ja0363258;;10804564;;10.1021/ol005654r;;10.1021/ja012610k;;12022838;;10.1021/ol035655u;;14602003;;10.1016/s0040-4039(03)00569-0;;10.1002/3527601775;;10.1016/s0022-1139(00)82723-2;;10.1021/jo981522o;;10.1021/jo991490k;;10814101;;10.1135/cccc19591667;;10.1016/s0040-4020(01)01182-6;;10.1016/s0022-1139(00)82723-2;;10.1021/jo000150s;;11149825;;10.1016/s0022-1139(03)00109-x,"""Novel Antipsychotic Drugs"", 1992, RAVEN PRESS, pages: 135 - 144;;M. DOOLEY ET AL., DRUGS AND AGING, vol. 12, 1998, pages 495 - 514;;J.N. JOYCE: ""The Dopamine D3 Receptor as a Therapeutic Target for Antipsychotic and Antiparkinsonian Drugs"", PHARMACOLOGY AND THERAPEUTICS, vol. 90, 2001, pages 231 - 59;;P. SOKOLOFF ET AL.: ""Localization and Function of the D3 Dopamine Receptor"", ARZNEIM. FORSCH./DRUQ RES., vol. 42, no. 1, 1992, pages 224;;P. SOKOLOFF ET AL.: ""Molecular Cloning and Characterization of a Novel Dopamine Receptor (D3) as a Target for Neuroleptics"", NATURE, vol. 347, 1990, pages 146;;""Fortschritte der Arzneimit- telforschung"", vol. 10, 1966, BIRKHÄUSER VERLAG, pages: 224;;J. MARCH: ""Advanced Organic Chemistry, 3rd edition,"", 1985, JOHN WILEY & SONS, pages: 444;;EUROPEAN J. ORG. CHEM., no. 13, 2002, pages 2094 - 2108;;TETRAHEDRON, vol. 57, no. 27, 2001, pages 5885 - 5895;;BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 10, no. 8, 2000, pages 835 - 838;;SYNTHESIS, no. 1, 2000, pages 103 - 108;;J. AM. CHEM. SOC., vol. 123, no. 28, 2001, pages 6801 - 6808;;J. ORG. CHEM, vol. 67, no. 11, 2002, pages 3718 - 3723;;J. CHEM. SOC., PERKIN TRANSACTION I: ORGANIC AND BIO-ORGANIC CHEMISTRY, no. 21, 1999, pages 3089 - 3104;;TETRAHEDRON ASYMMETRY, vol. 8, no. 20, 1997, pages 3387 - 3391;;BIOORGANIC AND MEDICINAL CHEMISTRY LETT., vol. 12, no. 7, 2002, pages 2443 - 2446;;BIOORGANIC AND MEDICINAL CHEMISTRY LETT., vol. 12, no. 5, 2002, pages 795 - 798;;JERRY MARCH: ""Advanced Organic Chemistry, 3rd ed."", 1985, J. WILEY & SONS, pages: 370,373,;;SYNTH. COMMUN., vol. 16, 1986, pages 267;;J. HETEROCYCL. CHEM., vol. 16, 1979, pages 1525;;ORG. LETT., vol. 2, 2000, pages 1101;;J. AM. CHEM. SOC., vol. 124, 2002, pages 6043;;ORG. LETT., vol. 5, 2003, pages 4373;;TETRAHEDRON LETT., vol. 44, 2003, pages 3385;;J. ORG. CHEM., vol. 68, no. 2993, pages 8274 - 8276;;J. ORG. CHEM., vol. 65, 2000, pages 2612;;TETRAHEDRON ASYM., vol. 10, 1999, pages 1831;;TETRAHEDRON, vol. 59, no. 34, 2003, pages 6545;;BIOORG. MED. CHEM., vol. 7, no. 5, 1999, pages 665;;JERRY MARCH: ""Advanced Organic Chemistry, 3rd ed."", JOHN WILEY, pages: 348FF;;JERRY MARCH: ""Advanced Organic Chemistry, 3rd ed."", JOHN WILEY, pages: 1093FF;;JERRY MARCH: ""Advanced Organic Chemistry, 3rd ed."", JOHN WILEY, pages: 468;;TETRAHEDRON, vol. 55, no. 33, 1999, pages 10243 - 10252;;J. MED. CHEM., vol. 40, no. 22, 1997, pages 3679 - 3686;;SYNTHETIC COMMUNICATIONS, vol. 23, no. 5, 1993, pages 591 - 599;;J. MARCH: ""Advanced Organic Chemistry, 3rd ed."", 1985, J. WILEY & SONS, pages: 1183;;ONO ET AL., CHEM. IND., 1983, pages 480;;LALANCETTE ET AL., CAN. J. CHEM., vol. 49, 1971, pages 2990;;BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 12, no. 15, 2002, pages 1917 - 1919;;J. MED. CHEM., vol. 45, no. 21, 2002, pages 4679 - 4688;;JERRY MARCH: ""Advanced Organic Chemistry, 3rd ed."", JOHN WILEY, pages: 476;;J. ORG. CHEM, vol. 52, 1987, pages 235;;JERRY MARCH: ""Advanced Organic Chemistry, 3rd ed."", JOHN WILEY, pages: 845;;CHEM. PHARM. BULL., vol. 33, 1985, pages 2762 - 66;;J. HETEROCYCLIC CHEMISTRY, 1996, pages 1995 - 2005;;J. HETEROCYCLIC CHEMISTRY, vol. 38, 2001, pages 1039 - 1044;;TETRAHEDRON LETTERS, vol. 33, no. 44, 1992, pages 6607 - 10;;HETEROCYCLES, vol. 48, no. 12, 1998, pages 2535 - 2541;;TETRAHEDRON, vol. 52, 1996, pages 59;;TETRAHEDRON, vol. 58, 2002, pages 9865 - 9870;;TETRAHEDRON, vol. 43, 1987, pages 2203 - 2212;;J. ORG. CHEM., vol. 53, 1988, pages 2390 - 2392;;SYNLETT, vol. 4, 1998, pages 379 - 380;;J. AM. CHEM. SOC., vol. 125, 2003, pages 12527 - 12530;;ORG. LETT., vol. 2, 2000, pages 1101 - 1104;;J. AM. CHEM. SOC., vol. 124, 2002, pages 6043 - 6048;;ORG. LETT., vol. 5, 2003, pages 4373 - 4376;;TETRAHEDRON LETT., vol. 44, 2003, pages 3385 - 3386;;TETRAHEDRON, vol. 57, 2001, pages 9199,9225;;""Microwaves in Organic Synthesis"", 2002, WILEY-VCH;;JOURNAL OF FLUORINE CHEMISTR, vol. 43, 1989, pages 371 - 377;;J. ORG. CHEM., vol. 59, 1994, pages 2898 - 22901;;TETRAHEDRON LETTERS, 1998, pages 7305 - 6;;J. ORG. CHEM., vol. 63, 1998, pages 9587 - 9589;;SYNTHESIS, 1987, pages 920 - 21;;HETEROCYCLES, vol. 55, no. 9, 2001, pages 1789 - 1803;;J. ORG. CHEM., vol. 65, 2000, pages 1399 - 1406;;EUR. J. MED. CHEM., vol. 36, 2002, pages 809 - 828;;TETRAHEDRON LETTERS, vol. 33, no. 50, 1991, pages 7787 - 7788;;J. ORG. CHEM., vol. 25, 1960, pages 1824 - 26;;SYNTHESIS, 1998, pages 36 - 38;;J. AM. CHEM. SOC., vol. 74, 1950, pages 4890 - 92;;CHEMISCHE BERICHTE, 1960, pages 1208 - 11;;CHEMISCHE BERICHTE, vol. 95, 1960, pages 230 - 235;;COLLECTION CZECHOSLOW. CHEM. COMM., vol. 24, 1959, pages 1667 - 1671;;AUSTR. J. CHEM., vol. 19, 1966, pages 2321 - 30;;CHEMIKER-ZEITUNG, vol. 101, no. 6, 1977, pages 305 - 7;;TETRAHEDRON, vol. 58, 2002, pages 887 - 890;;SYNTHESIS, 1983, pages 641 - 645;;JOURNAL OF FLUORINE CHEMISTRY, vol. 43, 1989, pages 371 - 377;;JOURNAL OF ORGANIC CHEMISTRY, vol. 65, 2000, pages 8848 - 8856;;JOURNAL OF FLUORINE CHEMISTRY, vol. 122, 2003, pages 243 - 246;;JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 109, 1987, pages 2435 - 4;;FIEDLER, H.P.: ""Encyclopedia of auxiliary substances for pharmacy, cosmetics and related fields, 4th edition,"", 1996, AULENDORF: ECV-EDITIO-KANTOR-VERLAG",DISCONTINUED
26,TW,B,TW I364414 B,036-757-334-875-730,2012-05-21,2012,TW 94136070 A,2005-10-14,US 61887804 P,2004-10-14,Phenylpyrrolidine dopamine d3 receptor antagonists,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,HAUPT ANDREAS;;GRANDEL ROLAND;;BRAJE WILFRIED;;DRESCHER KARLA;;UNGER LILIANE;;TURNER SEAN C;;HENRY CHRISTOPHE;;BEYERBACH ARMIN;;BACKFISCH GISELA;;LUBISCH WILFRIED,,https://lens.org/036-757-334-875-730,Granted Patent,no,0,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,,,0,0,,,,INACTIVE
27,CN,B,CN 101039904 B,128-109-141-559-213,2014-09-24,2014,CN 200580035304 A,2005-10-14,EP 2005011106 W;;US 61887804 P,2004-10-14,Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,DRESCHER KARLA;;UNGER LILIANE;;HAUPT ANDREAS;;BACKFISCH GISELA;;HENRY CHRISTOPHE;;BRAJE WILFRIED;;BEYERBACH ARMIN;;LUBISCH WILFRIED;;GRANDEL ROLAND;;TURNER SEAN C,ABBVIE GERMANY GMBH + CO. KG (2013-09-11),https://lens.org/128-109-141-559-213,Granted Patent,no,0,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,C07D207/09;;A61K31/397;;A61K31/445;;A61P25/16;;C07D205/04;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14,,0,0,,,,INACTIVE
28,HK,A1,HK 1111681 A1,180-653-683-452-079,2008-08-15,2008,HK 08100350 A,2008-01-10,EP 2005011106 W;;US 61887804 P,2004-10-14,HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN C;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED,,https://lens.org/180-653-683-452-079,Patent Application,no,0,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,A61K/;;A61P/;;C07D/,,0,0,,,,DISCONTINUED
29,CA,C,CA 2583983 C,056-281-767-442-572,2013-07-16,2013,CA 2583983 A,2005-10-14,US 61887804 P;;EP 2005011106 W,2004-10-14,HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH2 or CHR3; R1 is H, C,-C6-alkyl, C,-C6-alkyl substituted by C3-C6-cycloalkyl, Cl-C6-hydroxyalkyl, fluorinated C,-C6-alkyl, C3-C6-cycloalkyl, fluorinated C3-C6-cycloalkyl, C3-C6~ alkenyl, fluorinated C3-C6-alkenyl, formyl, acetyl or propionyl; R2, R3 and R4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF3; E is NR5 or CH2, wherein R5 is H or C1 -C3-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-~membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C4~alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra, wherein the variable Ra has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN C;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED,,https://lens.org/056-281-767-442-572,Granted Patent,no,0,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,C07D207/09;;A61K31/397;;A61K31/445;;A61P25/16;;C07D205/04;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14,,0,0,,,,INACTIVE
30,ZA,B,ZA 200703061 B,077-610-689-788-08X,2008-09-25,2008,ZA 200703061 A,2007-04-13,US 61887804 P,2004-10-14,"Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D, receptor","The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,KARLA DRESCHER;;LILIANE UNGER;;WILFRIED BRAJE;;CHRISOPHE HENRY;;ARMIN BEYERBACH;;ANDREAS HAUPT;;TURNER SEAN C;;ROLAND GRANDEL;;GISELA BACKFISCH;;WILFRIED LUBISCH,,https://lens.org/077-610-689-788-08X,Granted Patent,no,0,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,A61K/;;A61P/;;C07D/,,0,0,,,,ACTIVE
31,DE,D1,DE 602005027382 D1,170-838-246-378-040,2011-05-19,2011,DE 602005027382 T,2005-10-14,US 61887804 P;;EP 2005011106 W,2004-10-14,ZUR BEHANDLUNG VON AUF EINE MODULATION DES DOPAMIN-D3-REZEPTORS ANSPRECHENDE ERKRANKUNGEN GEEIGNETE HETEROCYCLISCHE VERBINDUNGEN,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN C;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED,,https://lens.org/170-838-246-378-040,Granted Patent,no,0,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,C07D207/09;;A61K31/397;;C07D205/04;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14,,0,0,,,,ACTIVE
32,TW,A,TW 200619195 A,088-354-602-137-479,2006-06-16,2006,TW 94136070 A,2005-10-14,US 61887804 P,2004-10-14,Phenylpyrrolidine dopamine D3 receptor antagonists,"The invention relates to compounds of the formula (I), , wherein n is 0, 1 or 2; G is CH2 or CHR3; R1 is H, C1-C6-alkyl, C1-C6-alkyl substituted by C3-C6-cycloalkyl, C1-C6-hydroxyalkyl, fluorinated C1-C6-alkyl, C3-C6-cycloalkyl, fluorinated Cs-Ce-cycloalkyl, C3-C6-alkenyl, fluorinated C3-C6-alkenyl, formyl, acetyl or propionyl; R2, R3 and R4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF3; E is NR5 or CH2, wherein R5 is H or C1-C3-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatorns selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C4-alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra, wherein the variable Ra has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,HAUPT ANDREAS;;GRANDEL ROLAND;;BRAJE WILFRIED;;DRESCHER KARLA;;UNGER LILIANE;;TURNER SEAN C;;HENRY CHRISTOPHE;;BEYERBACH ARMIN;;BACKFISCH GISELA;;LUBISCH WILFRIED,,https://lens.org/088-354-602-137-479,Patent of Addition,no,0,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,,,0,0,,,,INACTIVE
33,AU,A1,AU 2005/293698 A1,092-572-348-266-450,2006-04-20,2006,AU 2005/293698 A,2005-10-14,US 61887804 P;;EP 2005011106 W,2004-10-14,Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,LUBISCH WILFRIED;;GRANDEL ROLAND;;HAUPT ANDREAS;;TURNER SEAN C;;BEYERBACH ARMIN;;HENRY CHRISTOPHE;;BRAJE WILFRIED;;DRESCHER KARLA;;BACKFISCH GISELA;;UNGER LILIANE,ABBVIE DEUTSCHLAND GMBH & CO. KG (2013-08-08),https://lens.org/092-572-348-266-450,Patent Application,no,0,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,C07D207/09;;A61K31/397;;A61K31/445;;A61P25/16;;C07D205/04;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14,,0,0,,,,INACTIVE
34,KR,A,KR 20070084208 A,106-565-502-674-702,2007-08-24,2007,KR 20077010955 A,2005-10-14,US 61887804 P;;EP 2005011106 W,2004-10-14,HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH2 or CHR3; R1 is H, C,-C 6-alkyl, C,-C6-alkyl substituted by C3-C 6-cycloalkyl, Cl-C6-hydroxyalkyl, fluorinated C,-C6-alkyl, C3-C6-cycloalkyl, fluorinated C3-C6-cycloalkyl, C3-C 6-alkenyl, fluorinated C3-C6-alkenyl, formyl, acetyl or propionyl; R2, R3 and R4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF3; E is NR5 or CH2, wherein R5 is H or C 1 -C3-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5-or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5-or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C 4-alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra, wherein the variable Ra has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN C;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED,,https://lens.org/106-565-502-674-702,Patent Application,no,0,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,C07D211/26;;A61K31/397;;C07D401/04;;C07D403/04,,0,0,,,,INACTIVE
35,AU,B2,AU 2005/293698 B2,134-143-787-029-699,2011-12-15,2011,AU 2005/293698 A,2005-10-14,US 61887804 P;;EP 2005011106 W,2004-10-14,Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH or CHR; R is H, C,-C-alkyl, C,-C-alkyl substituted by C-C-cycloalkyl, C-C-hydroxyalkyl, fluorinated C,-C-alkyl, C-C-cycloalkyl, fluorinated C-C-cycloalkyl, C-C­ alkenyl, fluorinated C-C-alkenyl, formyl, acetyl or propionyl; R, R and R are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF; E is NR or CH, wherein R is H or C-C-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6- ­membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR, where R is H, C-C-alkyl, fluorinated C-C-alkyl, C-C­alkylcarbonyl or fluorinated C-C-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R, wherein the variable R has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBVIE DEUTSCHLAND,WILFRIED LUBISCH;;ROLAND GRANDEL;;ANDREAS HAUPT;;TURNER SEAN C;;ARMIN BEYERBACH;;CHRISTOPHE HENRY;;WILFRIED BRAJE;;KARLA DRESCHER;;GISELA BACKFISCH;;LILIANE UNGER,ABBVIE DEUTSCHLAND GMBH & CO. KG (2013-08-08),https://lens.org/134-143-787-029-699,Granted Patent,no,2,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,C07D207/09;;A61K31/397;;A61K31/445;;A61P25/16;;C07D205/04;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14,,0,0,,,,INACTIVE
36,EP,B1,EP 1814849 B1,119-524-006-707-588,2011-04-06,2011,EP 05805167 A,2005-10-14,EP 2005011106 W;;US 61887804 P,2004-10-14,HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN C;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED,"ABBVIE DEUTSCHLAND GMBH & CO KG, DE (2013-09-25);;ABBVIE DEUTSCHLAND GMBH & CO. KG (2013-11-21)",https://lens.org/119-524-006-707-588,Granted Patent,yes,2,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,C07D207/09;;A61K31/397;;A61K31/445;;A61P25/16;;C07D205/04;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14,,0,0,,,,ACTIVE
37,WO,A1,WO 2006/040182 A1,043-810-190-919-055,2006-04-20,2006,EP 2005011106 W,2005-10-14,US 61887804 P,2004-10-14,HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH2 or CHR3; R1 is H, C,-C6-alkyl, C,-C6-alkyl substituted by C3-C6-cycloalkyl, Cl-C6-hydroxyalkyl, fluorinated C,-C6-alkyl, C3-C6-cycloalkyl, fluorinated C3-C6-cycloalkyl, C3-C6&shy; alkenyl, fluorinated C3-C6-alkenyl, formyl, acetyl or propionyl; R2, R3 and R4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF3; E is NR5 or CH2, wherein R5 is H or C1 -C3-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6- &shy;membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C4&shy;alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra, wherein the variable Ra has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG;;DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN C;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED,DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN C;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED,,https://lens.org/043-810-190-919-055,Patent Application,yes,8,7,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,C07D207/09;;A61K31/397;;A61K31/445;;A61P25/16;;C07D205/04;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14,,16,5,066-203-166-874-90X;;103-874-089-842-134;;153-159-554-788-315;;003-413-381-149-348;;054-835-288-313-609,10.1038/347146a0;;1975644;;10.1016/s0040-4020(01)00527-0;;10.1016/s0960-894x(00)00110-4;;10782697;;10.1021/ja012610k;;12022838;;14535819;;10.1021/jo034643j,"ARZNEIM, FORSCH./DRUQ RES., vol. 42, no. 1, 1992, pages 224;;P. SOKOLOFF ET AL.: ""Molecular Cloning and Characterization of a Novel Dopamine Receptor (D3) as a Target for Neuroleptics"", NATURE, vol. 347, 1990, pages 146;;J. MARCH: ""Advanced Organic Chemistry"", 1985, JOHN WILEY & SONS, pages: 444FF;;EUROPEAN J. ORG. CHEM., vol. 13, 2002, pages 2094 - 2108;;TETRAHEDRON, vol. 57, no. 27, 2001, pages 5885 - 5895;;BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 10, no. 8, 2000, pages 835 - 838;;SYNTHESIS, vol. 1, 2000, pages 103 - 108;;JERRY MARCH: ""Advanced Organic Chemistry"", 1985, J. WILEY & SONS, pages: 370,373,;;SYNTH. COMMUN., vol. 16, 1986, pages 267;;J. HETEROCYCL. CHEM., vol. 16, 1979, pages 1525;;ORG. LETT., vol. 2, 2000, pages 1101;;J. AM. CHEM. SOC., vol. 124, 2002, pages 6043;;ORG. LETT., vol. 5, 2003, pages 4373;;TETRAHEDRON LETT., vol. 44, 2003, pages 3385;;J. ORG. CHEM., vol. 68, no. 2993, pages 8274 - 8276;;J. ORG. CHEM., vol. 65, 2000, pages 2612",PENDING
38,EP,A1,EP 1814849 A1,121-425-352-834-203,2007-08-08,2007,EP 05805167 A,2005-10-14,EP 2005011106 W;;US 61887804 P,2004-10-14,HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN C;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED,"ABBVIE DEUTSCHLAND GMBH & CO KG, DE (2013-09-25);;ABBVIE DEUTSCHLAND GMBH & CO. KG (2013-11-21)",https://lens.org/121-425-352-834-203,Patent Application,yes,0,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,C07D207/09;;A61K31/397;;A61K31/445;;A61P25/16;;C07D205/04;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14,,0,0,,,,ACTIVE
39,US,A1,US 2011/0160176 A1,038-436-960-417-169,2011-06-30,2011,US 86848010 A,2010-08-25,US 86848010 A;;US 66539907 A;;EP 2005011106 W;;US 61887804 P,2004-10-14,HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR,"The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C,-C 6 -alkyl, C,-C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C,-C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 , R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one or more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN C;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED,ABBVIE DEUTSCHLAND GMBH & CO KG (2012-11-01),https://lens.org/038-436-960-417-169,Patent Application,yes,4,4,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,A61K31/397;;A61K31/40;;A61K31/422;;A61K31/433;;A61K31/445;;A61K31/506;;A61P25/28;;C07D205/02;;C07D207/08;;C07D211/08;;C07D401/02;;C07D403/02;;C07D413/14;;C07D417/02,514/210.2;;548/567;;514/428;;546/268.1;;548/950;;544/242;;514/256;;548/127;;514/361;;548/215;;514/374;;546/184;;514/315,2,0,,,"""Autism,"" [retrieved on 14-05-2008]. Retrieved online via Internet, URL: http://www.nlm.nih.gov/medlineplus/autism.html;;""Anxiety,"" [retrieved on 14-05-2008]. Retrieved online via Internet, URL: http://www.nlm.nih.gov/medlineplus/anxiety.html",INACTIVE
40,EP,A1,EP 2311802 A1,140-698-950-839-605,2011-04-20,2011,EP 10183328 A,2005-10-14,EP 05805167 A;;US 61887804 P,2004-10-14,Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor,"The invention relates to compounds of the formula (I)
  
wherein 
n is 0,1 or 2; 
G is CH 2  or CHR 3 ; 
R 1  is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; 
R 2 , R 3  and R 4  are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; 
A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; 
E is NR 5  or CH 2 , wherein R 5  is H or C 1 -C 3 -alkyl; 
Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 3  is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a  has the meanings given in the claims and in the description; 
 
and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.",ABBOTT GMBH & CO KG,DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN C;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED,ABBVIE DEUTSCHLAND GMBH & CO KG (2013-10-16),https://lens.org/140-698-950-839-605,Patent Application,yes,9,0,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,C07D207/09;;A61K31/397;;A61K31/40;;A61K31/445;;A61P25/16;;A61P25/18;;A61P25/24;;C07D205/04;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14,,85,35,031-458-967-384-69X;;085-016-098-817-131;;031-627-809-128-054;;066-203-166-874-90X;;103-874-089-842-134;;153-159-554-788-315;;053-085-428-615-638;;035-808-495-317-968;;010-087-908-931-639;;065-555-816-456-156;;078-373-504-732-902;;003-413-381-149-348;;054-835-288-313-609;;052-262-000-217-696;;036-624-218-655-088;;041-638-530-303-448;;072-395-811-410-494;;033-407-244-083-669;;088-030-824-804-950;;115-078-430-515-443;;039-499-061-311-955;;014-469-296-911-520;;021-610-971-176-86X;;003-413-381-149-348;;070-808-757-271-461;;081-850-963-221-391;;038-914-505-670-473;;007-127-643-939-955;;027-712-609-296-602;;028-842-674-934-625;;036-969-629-931-052;;045-575-040-645-410;;028-842-674-934-625;;059-901-774-892-516;;122-078-475-262-658,9638397;;10.2165/00002512-199812060-00007;;10.1016/s0163-7258(01)00139-5;;11578658;;1586393;;10.1038/347146a0;;1975644;;10.1016/s0040-4020(01)00527-0;;10.1016/s0960-894x(00)00110-4;;10782697;;11448184;;10.1021/ja010654n;;12027685;;10.1021/jo011116w;;10.1016/s0957-4166(97)00470-9;;12161153;;10.1016/s0960-894x(02)00436-5;;11859005;;10.1016/s0960-894x(02)00024-0;;10.1021/ja012610k;;12022838;;14535819;;10.1021/jo034643j;;10.1016/s0040-4020(99)00550-5;;9357535;;10.1021/jm970396y;;10.1080/00397919308009817;;10.1139/v71-498;;12361394;;10.1021/jm020124h;;10.1016/s0040-4020(02)01297-8;;10.1016/s0040-4020(01)86803-4;;10.1021/jo00245a057;;14531697;;10.1021/ja0363258;;10804564;;10.1021/ol005654r;;10.1021/ja012610k;;12022838;;10.1021/ol035655u;;14602003;;10.1016/s0040-4039(03)00569-0;;10.1002/3527601775;;10.1016/s0022-1139(00)82723-2;;10.1021/jo981522o;;10.1021/jo991490k;;10814101;;10.1135/cccc19591667;;10.1016/s0040-4020(01)01182-6;;10.1021/jo991490k;;10814101;;10.1021/jo000150s;;11149825;;10.1016/s0022-1139(03)00109-x,"J.C. SCHWARTZ ET AL.: ""Novel Antipsychotic Drugs"", 1992, RAVEN PRESS, article ""The Dopamine D3 Receptor as a Target for Antipsychotics"", pages: 135 - 144;;M. DOOLEY ET AL., DRUGS AND AGING, vol. 12, 1998, pages 495 - 514;;J.N. JOYCE, PHARMACOLOGY AND THERAPEUTICS, vol. 90, 2001, pages 231 - 59;;P. SOKOLOFF ET AL.: ""Localization and Function of the D3 Dopamine Receptor"", ARZNEIM. FORSCH./DRUQ RES., vol. 42, no. 1, 1992, pages 224;;P. SOKOLOFF ET AL.: ""Molecular Cloning and Characterization of a Novel Dopamine Receptor (D3) as a Target for Neuroleptics"", NATURE, vol. 347, 1990, pages 146;;BASEL; STUTTGART: ""Fortschritte der Arzneimit- telforschung"", vol. 10, 1966, BIRKHAUSER VERLAG, pages: 224 FF;;J. MARCH: ""Advanced Organic Chemistry, 3rd edition,"", 1985, JOHN WILEY & SONS, pages: 444FF;;EUROPEAN J. ORG. CHEM., 2002, pages 2094 - 2108;;TETRAHEDRON, vol. 57, no. 27, 2001, pages 5885 - 5895;;BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 10, no. 8, 2000, pages 835 - 838;;SYNTHESIS, 2000, pages 103 - 108;;J. AM. CHEM. SOC., vol. 123, no. 28, 2001, pages 6801 - 6808;;J. ORG. CHEM, vol. 67, no. 11, 2002, pages 3718 - 3723;;J. CHEM. SOC., PERKIN TRANSACTION I: ORGANIC AND BIO-ORGANIC CHEMISTRY, 1999, pages 3089 - 3104;;TETRAHEDRON ASYMMETRY, vol. 8, no. 20, 1997, pages 3387 - 3391;;BIOORGANIC AND MEDICINAL CHEMISTRY LETT., vol. 12, no. 7, 2002, pages 2443 - 2446;;BIOORGANIC AND MEDICINAL CHEMISTRY LETT., vol. 12, no. 5, 2002, pages 795 - 798;;BIOORGANIC AND MEDICAL CHEMISTRY LETT., vol. 12, no. 7, pages 1269 - 1273;;JERRY MARCH: ""Advanced Organic Chemistry, 3rd ed."", 1985, J. WILEY & SONS, pages: 370 - 373;;SYNTH. COMMUN., vol. 16, 1986, pages 267;;J. HETEROCYCL. CHEM., vol. 16, 1979, pages 1525;;ORG. LETT., vol. 2, 2000, pages 1101;;J. AM. CHEM. SOC., vol. 124, 2002, pages 6043;;ORG. LETT., vol. 5, 2003, pages 4373;;TETRAHEDRON LETT., vol. 44, 2003, pages 3385;;J. ORG. CHEM., vol. 68, no. 2993, pages 8274 - 8276;;J. ORG. CHEM., vol. 65, 2000, pages 2612;;TETRAHEDRON ASYM., vol. 10, 1999, pages 1831;;TETRAHEDRON, vol. 59, no. 34, 2003, pages 6545;;BIOORG. MED. CHEM., vol. 7, no. 5, 1999, pages 665;;JERRY MARCH: ""Advanced Organic Chemistry, 3rd edition,"", JOHN WILEY, pages: 348FF;;JERRY MARCH: ""Advanced Organic Chemistry, 3rd edition,"", JOHN WILEY, pages: 1093FF;;JERRY MARCH: ""Advanced Organic Chemistry, 3rd edition,"", JOHN WILEY, pages: 468FF;;TETRAHEDRON, vol. 55, no. 33, 1999, pages 10243 - 10252;;J. MED. CHEM., vol. 40, no. 22, 1997, pages 3679 - 3686;;SYNTHETIC COMMUNICATIONS, vol. 23, no. 5, 1993, pages 591 - 599;;J. MARCH: ""Advanced Organic Chemistry, 3rd edition,"", 1985, J. WILEY & SONS, pages: 1183;;ONO ET AL., CHEM. IND. (LONDON), 1983, pages 480;;LALANCETTE ET AL., CAN. J. CHEM., vol. 49, 1971, pages 2990;;BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 12, no. 15, 2002, pages 1917 - 1919;;J. MED. CHEM., vol. 45, no. 21, 2002, pages 4679 - 4688;;JERRY MARCH: ""Advanced Organic Chemistry, 3rd edition,"", JOHN WILEY, pages: 476 FF;;J. ORG. CHEM, vol. 52, 1987, pages 235;;JERRY MARCH: ""Advanced Organic Chemistry, 3rd edition,"", JOHN WILEY, pages: 845 FF;;CHEM. PHARM. BULL., vol. 33, 1985, pages 2762 - 66;;J. HETEROCYCLIC CHEMISTRY, 1996, pages 1995 - 2005;;J. HETEROCYCLIC CHEMISTRY, vol. 38, 2001, pages 1039 - 1044;;TETRAHEDRON LETTERS, vol. 33, no. 44, 1992, pages 6607 - 10;;HETEROCYCLES, vol. 48, no. 12, 1998, pages 2535 - 2541;;TETRAHEDRON, vol. 52, 1996, pages 59;;TETRAHEDRON, vol. 58, 2002, pages 9865 - 9870;;TETRAHEDRON, vol. 43, 1987, pages 2203 - 2212;;J. ORG. CHEM., vol. 53, 1988, pages 2390 - 2392;;SYNLETT, vol. 4, 1998, pages 379 - 380;;J. AM. CHEM. SOC., vol. 125, 2003, pages 12527 - 12530;;ORG. LETT., vol. 2, 2000, pages 1101 - 1104;;J. AM. CHEM. SOC., vol. 124, 2002, pages 6043 - 6048;;ORG. LETT., vol. 5, 2003, pages 4373 - 4376;;TETRAHEDRON LETT., vol. 44, 2003, pages 3385 - 3386;;TETRAHEDRON, vol. 57, 2001, pages 9199 - 9225;;""Microwaves in Organic Synthesis"", 2002, WILEY-VCH;;JOURNAL OF FLUORINE CHEMISTRY, vol. 43, 1989, pages 371 - 377;;J. ORG. CHEM., vol. 59, 1994, pages 2898 - 22901;;TETRAHEDRON LETTERS, 1998, pages 7305 - 6;;J. ORG. CHEM., vol. 63, 1998, pages 9587 - 9589;;SYNTHESIS, 1987, pages 920 - 21;;HETEROCYCLES, vol. 55, no. 9, 2001, pages 1789 - 1803;;ORG. CHEM., vol. 65, 2000, pages 1399 - 1406;;EUR. J. MED. CHEM., vol. 36, 2002, pages 809 - 828;;TETRAHEDRON LETTERS, vol. 33, no. 50, 1991, pages 7787 - 7788;;J. ORG. CHEM., vol. 25, 1960, pages 1824 - 26;;SYNTHESIS, 1998, pages 36 - 38;;J. AM. CHEM. SOC., vol. 74, 1950, pages 4890 - 92;;CHEMISCHE BERICHTE, 1960, pages 1208 - 11;;CHEMISCHE BERICHTE, vol. 95, 1960, pages 230 - 235;;COLLECTION CZECHOSLOW. CHEM. COMM., vol. 24, 1959, pages 1667 - 1671;;AUSTR. J. CHEM., vol. 19, 1966, pages 2321 - 30;;CHEMIKER-ZEITUNG, vol. 101, no. 6, 1977, pages 305 - 7;;TETRAHEDRON, vol. 58, 2002, pages 887 - 890;;SYNTHESIS, 1983, pages 641 - 645;;J. ORG. CHEM., vol. 65, 2000, pages 1399 - 1406;;JOURNAL OF ORGANIC CHEMISTRY, vol. 65, 2000, pages 8848 - 8856;;JOURNAL OF FLUORINE CHEMISTRY, vol. 122, 2003, pages 243 - 246;;JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 109, 1987, pages 2435 - 4;;FIEDLER, H.P.: ""Lexikon der Hilfsstoffe fur Pharmazie, Kos- metik und angrenzende Gebiete, 4th edition"", 1996, AULENDORF: ECV-EDITIO-KANTOR-VERLAG",DISCONTINUED
41,US,B2,US 7851463 B2,183-913-530-307-281,2010-12-14,2010,US 66539905 A,2005-10-14,US 66539905 A;;US 61887804 P;;EP 2005011106 W,2004-10-14,Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor,The invention relates to compounds of the formula (I). The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.,ABBOTT GMBH & CO KG,DRESCHER KARLA;;HAUPT ANDREAS;;UNGER LILIANE;;TURNER SEAN C;;BRAJE WILFRIED;;GRANDEL ROLAND;;HENRY CHRISTOPHE;;BACKFISCH GISELA;;BEYERBACH ARMIN;;LUBISCH WILFRIED,ABBOTT GMBH & CO. KG (2007-06-25);;ABBVIE DEUTSCHLAND GMBH & CO KG (2012-11-01),https://lens.org/183-913-530-307-281,Granted Patent,yes,8,2,31,31,0,C07D205/04;;C07D207/09;;C07D211/28;;C07D401/04;;C07D401/12;;C07D403/04;;C07D405/12;;C07D409/12;;C07D413/10;;C07D413/12;;C07D413/14;;A61P25/00;;A61P25/16;;A61P25/18;;A61P25/24;;A61P25/28;;A61P43/00;;C07D211/26;;C07D401/04;;C07D403/04;;A61K31/397;;C07D413/14;;C07D401/04;;C07D413/12;;C07D205/04;;C07D409/12;;C07D211/28;;C07D413/10;;C07D405/12;;C07D403/04;;C07D207/09;;C07D401/12,A61K31/397;;A61K31/40;;A61K31/4439;;A61K31/506;;C07D207/04;;C07D239/42;;C07D401/04,514/210.2;;514/256;;514/343;;514/429;;544/322;;546/268.1;;546/276.4;;548/577,11,9,031-458-967-384-69X;;085-016-098-817-131;;066-203-166-874-90X;;085-016-098-817-131;;067-688-210-340-740;;094-224-230-279-493;;009-976-414-319-663;;055-377-691-026-15X;;007-175-975-489-686,9638397;;10.2165/00002512-199812060-00007;;10.1016/s0163-7258(01)00139-5;;11578658;;10.1038/347146a0;;1975644;;10.1016/s0163-7258(01)00139-5;;11578658;;15619116;;10.1007/s00213-004-2096-z;;15960988;;pmc3732040;;10.1016/j.brainresrev.2004.12.033;;14506325;;10691804;;10.1046/j.1365-201x.2000.00665.x;;10.1037//0735-7044.117.1.46;;10.1037/0735-7044.117.1.46;;12619907,"J.C. Schwartz et al., The Dopamine D3 Receptor as a Target for Antipsychotics, in Novel Antipsychotic Drugs, H.Y. Meltzer, Ed. Raven Press, New York, 1992, pp. 135-144.;;M. Dooley et al., Drugs and Aging 1998, 12, 495-514.;;J. N. Joyce, Pharmacology and Therapeutics 2001, 90, pp. 231-259 ""The Dopamine D3 Receptor as a Therapeutic Target for Antipsychotic and Antiparkinsonian Drugs"".;;P. Sokoloff et al., Localization and Function of the D3 Dopamine Receptor, Arzneim. Frosch./Drug Res. 42(1), 224 (1992).;;P. Sokoloff et al., Molecular Cloning and Characterization of a Novel Dopamine Receptor (D3) as a Target for Neuroleptics, Nature, 347, 146 (1990).;;Joyce, J.N. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacology and Therapeutics, 2001;90:231-59.;;Laszy, J., et al. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Pscyhopharmacology, 2005;179:567-75.;;Heidbreder, C.A., et al. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Research Reviews, 2005;49:77-105.;;Rogoz, Z., et al. Anxiolytic-like effects of preferential dopamine D3 receptor agonists in an animal model. Polish Journal of Pharmacology, 2003;55:449-54.;;Muhlbauer B., et al.. Dopamine D3 receptors in the rat kidney: role in physiology and pathophysiology. Acta Physiologica Scandinavica, 2000;168(1):219-23.;;Benoit S.C., et al. Altered feeding responses in mice with targeted disruption of the dopamine-3 receptor gene. Behavioral Neuroscience, 2003;117(1):46-54.",INACTIVE
42,CN,A,CN 103839955 A,094-222-101-553-135,2014-06-04,2014,CN 201310722242 A,2008-04-18,CN 200880020973 A;;US 91258107 P;;US 95884607 P;;US 97021107 P;;US 2644008 P;;US 2665008 P;;US 2848108 P;;US 4637908 P,2007-04-18,"MATERIALS, SYSTEMS AND METHODS FOR OPTOELECTRONIC DEVICES","A photodetector is described along with corresponding materials, systems, and methods. The photodetector comprises an integrated circuit and at least two optically sensitive layers. A first optically sensitive layer is over at least a portion of the integrated circuit, and a second optically sensitive layer is over the first optically sensitive layer. Each optically sensitive layer is interposed between two electrodes. The two electrodes include a respective first electrode and a respective second electrode. The integrated circuit selectively applies a bias to the electrodes and reads signals from the optically sensitive layers. The signal is related to the number of photons received by the respective optically sensitive layer.",INVISAGE TECHNOLOGIES INC,SARGENT EDWARD HARTLEY;;KLEM ETHAN JACOB DUKENFIELD;;MACNEIL DEAN DELEHANTY;;SNELGROVE WILLIAM MARTIN;;PATTANTYUS-ABRAHAM ANDRAS GEZA;;KONSTANTATOS GERASIMOS;;CLIFFORD JASON PAUL;;TANG JIANG;;JOHNSTON KEITH WILLIAM;;LEVINA LARISSA;;HINDS SEAN O'REILLY;;FIFE KEITH GLEN;;AGHAJANIAN ARTHUR;;BRADING MICHAEL CHARLES;;DELLA NAVE PIERRE HENRI RENE;;DONG MILTON;;HUNTER KEVIN;;IVANOV IGOR CONSTANTIN;;LEE JEES JAN YOUNG;;OLIVER STEVEN DAVID;;TIAN HUI;;ADAMS IAN STUART;;HOOGLAND SJOERD;;FISCHER ARMIN;;CHIK RAYMOND,,https://lens.org/094-222-101-553-135,Patent Application,no,0,16,52,54,0,H01L27/14601;;H01L27/14603;;H01L27/14609;;H01L27/14647;;H01L27/14652;;H01L27/14687;;H01L27/14692;;H01L31/036;;H01L27/14641;;H01L31/1013;;G06V40/1318;;H01L27/14601;;H01L27/14603;;H01L27/14609;;H01L27/14647;;H01L27/14652;;H01L27/14687;;H01L27/14692;;H01L31/036;;H01L27/14641;;H01L31/1013,H01L27/146;;H01L31/036,,0,0,,,,ACTIVE
43,CN,B,CN 102017147 B,100-356-722-257-047,2014-01-29,2014,CN 200880020973 A,2008-04-18,US 2008/0060947 W;;US 91258107 P;;US 95884607 P;;US 97021107 P;;US 2644008 P;;US 2665008 P;;US 2848108 P;;US 4637908 P,2007-04-18,"Materials, systems and methods for optoelectronic devices",,INVISAGE TECHNOLOGIES INC,SARGENT EDWARD HARTLEY;;KLEM ETHAN JACOB DUKENFIELD;;MACNEIL DEAN DELEHANTY;;SNELGROVE WILLIAM MARTIN;;PATTANTYUS-ABRAHAM ANDRAS GEZA;;KONSTANTATOS GERASIMOS;;CLIFFORD JASON PAUL;;TANG JIANG;;JOHNSTON KEITH WILLIAM;;LEVINA LARISSA;;HINDS SEAN O'REILLY;;FIFE KEITH GLEN;;AGHAJANIAN ARTHUR;;BRADING MICHAEL CHARLES;;DELLA NAVE PIERRE HENRI RENE;;DONG MILTON;;HUNTER KEVIN;;IVANOV IGOR CONSTANTIN;;LEE JEES JAN YOUNG;;OLIVER STEVEN DAVID;;TIAN HUI;;ADAMS IAN STUART;;HOOGLAND SJOERD;;FISCHER ARMIN;;CHIK RAYMOND,,https://lens.org/100-356-722-257-047,Granted Patent,no,0,7,52,54,0,H01L27/14601;;H01L27/14603;;H01L27/14609;;H01L27/14647;;H01L27/14652;;H01L27/14687;;H01L27/14692;;H01L31/036;;H01L27/14641;;H01L31/1013;;G06V40/1318;;H01L27/14601;;H01L27/14603;;H01L27/14609;;H01L27/14647;;H01L27/14652;;H01L27/14687;;H01L27/14692;;H01L31/036;;H01L27/14641;;H01L31/1013,H01L27/14,,0,0,,,,ACTIVE
44,WO,A2,WO 2008/131313 A2,172-341-126-501-357,2008-10-30,2008,US 2008/0060947 W,2008-04-18,US 91258107 P;;US 95884607 P;;US 97021107 P;;US 2644008 P;;US 2665008 P;;US 2848108 P;;US 4637908 P,2007-04-18,MATERIALS SYSTEMS AND METHODS FOR OPTOELECTRONIC DEVICES,"A photodetector is described along with corresponding materials, systems, and methods. The photodetector comprises an integrated circuit and at least two optically sensitive layers. A first optically sensitive layer is ovei at least a poition of the integrated circuit, and a second optically sensitive layer is over the fust optically sensitive layer Each optically sensitive layer is interposed between two electrodes. The two electrodes include a respective first electrode and a respective second electrode The integrated circuit selectively applies a bias to the electrodes and reads signals from the optically sensitive layers The signal is related to the number of photons received by the respective optically sensitive layer",INVISAGE TECHNOLOGIES INC;;SARGENT EDWARD HARTLEY;;KLEM ETHAN JACOB DUKENFIELD;;MACNEIL DEAN DELEHANTY;;SNELGROVE WILLIAM MARTIN;;PATTANTYUS-ABRAHAM ANDRAS GEZA;;KONSTANTATOS GERASIMOS;;CLIFFORD JASON PAUL;;TANG JIANG;;JOHNSTON KEITH WILLIAM;;LEVINA LARISSA;;HINDS SEAN O'REILLY;;FIFE KEITH GLEN;;AGHAJANIAN ARTHUR;;BRADING MICHAEL CHARLES;;DELLA NAVE PIERRE HENRI RENE;;DONG MILTON;;HUNTER KEVIN;;IVANOV IGOR CONSTANTIN;;LEE JEES JAN YOUNG;;OLIVER STEVEN DAVID;;TIAN HUI;;ADAMS IAN STUART;;HOOGLAND SJOERD;;FISCHER ARMIN;;CHIK RAYMOND,SARGENT EDWARD HARTLEY;;KLEM ETHAN JACOB DUKENFIELD;;MACNEIL DEAN DELEHANTY;;SNELGROVE WILLIAM MARTIN;;PATTANTYUS-ABRAHAM ANDRAS GEZA;;KONSTANTATOS GERASIMOS;;CLIFFORD JASON PAUL;;TANG JIANG;;JOHNSTON KEITH WILLIAM;;LEVINA LARISSA;;HINDS SEAN O'REILLY;;FIFE KEITH GLEN;;AGHAJANIAN ARTHUR;;BRADING MICHAEL CHARLES;;DELLA NAVE PIERRE HENRI RENE;;DONG MILTON;;HUNTER KEVIN;;IVANOV IGOR CONSTANTIN;;LEE JEES JAN YOUNG;;OLIVER STEVEN DAVID;;TIAN HUI;;ADAMS IAN STUART;;HOOGLAND SJOERD;;FISCHER ARMIN;;CHIK RAYMOND,,https://lens.org/172-341-126-501-357,Patent Application,yes,3,64,52,54,0,H01L27/14601;;H01L27/14603;;H01L27/14609;;H01L27/14647;;H01L27/14652;;H01L27/14687;;H01L27/14692;;H01L31/036;;H01L27/14641;;H01L31/1013;;G06V40/1318;;H01L27/14601;;H01L27/14603;;H01L27/14609;;H01L27/14647;;H01L27/14652;;H01L27/14687;;H01L27/14692;;H01L31/036;;H01L27/14641;;H01L31/1013,H01J23/02,,2,1,004-980-130-267-232,10.1016/1047-3203(90)90002-d,"BORGEFORS ET AL.: ""JOURNAL OF VISUAL COMMUNICATION AND IMAGE REPRESENTATION"", vol. I, 1 November 1990, ACADEMIC PRESS, INC, article ""A semiregular image grid"", pages: 127 - 136;;See also references of EP 2143141A4",PENDING
45,EP,A1,EP 2667412 A1,094-503-693-632-064,2013-11-27,2013,EP 13004049 A,2008-04-18,US 2008/0060947 W;;US 91258107 P;;US 95884607 P;;US 97021107 P;;US 2644008 P;;US 2665008 P;;US 2848108 P;;US 4637908 P,2007-04-18,"Materials, systems and methods for optoelectronic devices","A photodetector is described along with corresponding materials, systems, and methods. The photodetector comprises an integrated circuit and at least two optically sensitive layers. A first optically sensitive layer is ovei at least a poition of the integrated circuit, and a second optically sensitive layer is over the fust optically sensitive layer Each optically sensitive layer is interposed between two electrodes. The two electrodes include a respective first electrode and a respective second electrode The integrated circuit selectively applies a bias to the electrodes and reads signals from the optically sensitive layers The signal is related to the number of photons received by the respective optically sensitive layer
",INVISAGE TECHNOLOGIES INC,SARGENT EDWARD HARTLEY;;KLEM ETHAN JACOB DUKENFIELD;;MACNEIL DEAN DELEHANTY;;SNELGROVE WILLIAM MARTIN;;PATTANTYUS-ABRAHAM ANDRAS GEZA;;KONSTANTATOS GERASIMOS;;CLIFFORD JASON PAUL;;TANG JIANG;;JOHNSTON KEITH WILLIAM;;LEVINA LARISSA;;HINDS SEAN O'REILLY;;FIFE KEITH GLEN;;AGHAJANIAN ARTHUR;;BRADING MICHAEL CHARLES;;DELLA NAVE PIERRE HENRI RENE;;DONG MILTON;;HUNTER KEVIN;;IVANOV IGOR CONSTANTIN;;LEE JEES JAN YOUNG;;OLIVER STEVEN DAVID;;TIAN HUI;;ADAMS IAN STUART;;HOOGLAND SJOERD;;FISCHER ARMIN;;CHIK RAYMOND,"INVISAGE TECHNOLOGIES, INC. (2017-08-30)",https://lens.org/094-503-693-632-064,Patent Application,yes,4,0,52,54,0,H01L27/14601;;H01L27/14603;;H01L27/14609;;H01L27/14647;;H01L27/14652;;H01L27/14687;;H01L27/14692;;H01L31/036;;H01L27/14641;;H01L31/1013;;G06V40/1318;;H01L27/14601;;H01L27/14603;;H01L27/14609;;H01L27/14647;;H01L27/14652;;H01L27/14687;;H01L27/14692;;H01L31/036;;H01L27/14641;;H01L31/1013,H01L27/146;;H01L31/036,,0,0,,,,DISCONTINUED
46,WO,A3,WO 2008/131313 A3,062-952-829-986-914,2008-12-11,2008,US 2008/0060947 W,2008-04-18,US 91258107 P;;US 95884607 P;;US 97021107 P;;US 2644008 P;;US 2665008 P;;US 2848108 P;;US 4637908 P,2007-04-18,MATERIALS SYSTEMS AND METHODS FOR OPTOELECTRONIC DEVICES,"A photodetector is described along with corresponding materials, systems, and methods. The photodetector comprises an integrated circuit and at least two optically sensitive layers. A first optically sensitive layer is ovei at least a poition of the integrated circuit, and a second optically sensitive layer is over the fust optically sensitive layer Each optically sensitive layer is interposed between two electrodes. The two electrodes include a respective first electrode and a respective second electrode The integrated circuit selectively applies a bias to the electrodes and reads signals from the optically sensitive layers The signal is related to the number of photons received by the respective optically sensitive layer",INVISAGE TECHNOLOGIES INC;;SARGENT EDWARD HARTLEY;;KLEM ETHAN JACOB DUKENFIELD;;MACNEIL DEAN DELEHANTY;;SNELGROVE WILLIAM MARTIN;;PATTANTYUS-ABRAHAM ANDRAS GEZA;;KONSTANTATOS GERASIMOS;;CLIFFORD JASON PAUL;;TANG JIANG;;JOHNSTON KEITH WILLIAM;;LEVINA LARISSA;;HINDS SEAN O'REILLY;;FIFE KEITH GLEN;;AGHAJANIAN ARTHUR;;BRADING MICHAEL CHARLES;;DELLA NAVE PIERRE HENRI RENE;;DONG MILTON;;HUNTER KEVIN;;IVANOV IGOR CONSTANTIN;;LEE JEES JAN YOUNG;;OLIVER STEVEN DAVID;;TIAN HUI;;ADAMS IAN STUART;;HOOGLAND SJOERD;;FISCHER ARMIN;;CHIK RAYMOND,SARGENT EDWARD HARTLEY;;KLEM ETHAN JACOB DUKENFIELD;;MACNEIL DEAN DELEHANTY;;SNELGROVE WILLIAM MARTIN;;PATTANTYUS-ABRAHAM ANDRAS GEZA;;KONSTANTATOS GERASIMOS;;CLIFFORD JASON PAUL;;TANG JIANG;;JOHNSTON KEITH WILLIAM;;LEVINA LARISSA;;HINDS SEAN O'REILLY;;FIFE KEITH GLEN;;AGHAJANIAN ARTHUR;;BRADING MICHAEL CHARLES;;DELLA NAVE PIERRE HENRI RENE;;DONG MILTON;;HUNTER KEVIN;;IVANOV IGOR CONSTANTIN;;LEE JEES JAN YOUNG;;OLIVER STEVEN DAVID;;TIAN HUI;;ADAMS IAN STUART;;HOOGLAND SJOERD;;FISCHER ARMIN;;CHIK RAYMOND,,https://lens.org/062-952-829-986-914,Search Report,yes,11,5,52,54,0,H01L27/14601;;H01L27/14603;;H01L27/14609;;H01L27/14647;;H01L27/14652;;H01L27/14687;;H01L27/14692;;H01L31/036;;H01L27/14641;;H01L31/1013;;G06V40/1318;;H01L27/14601;;H01L27/14603;;H01L27/14609;;H01L27/14647;;H01L27/14652;;H01L27/14687;;H01L27/14692;;H01L31/036;;H01L27/14641;;H01L31/1013,H01L27/14,,4,4,063-615-789-778-393;;058-644-568-355-145;;045-115-412-177-973;;089-503-525-349-787,12612665;;10.1038/nmat844;;10.1063/1.1923189;;10.1063/1.1517750;;10.1109/jrproc.1959.287039,"BUHRO ET AL.: ""Semiconductor Nanocrystals: Shape Matters"", NATURE MATERIALS, vol. 2, March 2006 (2006-03-01), pages 138 - 139, XP007902949;;FISCHBEIN M.D. ET AL: ""CdSe nanocrystal quantum-dot memory"", APPLIED PHYSICS LETTERS, vol. 86, 2005, pages 193106-1 - 193106-3, XP012065373;;ZHENGMAO YE ET AL: ""InAs quantum dot infrared photodetectors with InGaAs strain-relief cap layers"", JOURNAL OF APPLIED PHYSICS, vol. 92, no. 12, 15 December 2002 (2002-12-15), pages 7462 - 7468, XP012056810;;CASHMAN R.J.: ""Film-Type Infrared Photoconductors"", PROCEEDINGS OF THE IRE, 1959, pages 1471 - 1475, XP011156661",PENDING
47,CN,A,CN 102017147 A,122-904-787-256-638,2011-04-13,2011,CN 200880020973 A,2008-04-18,US 2008/0060947 W;;US 91258107 P;;US 95884607 P;;US 97021107 P;;US 2644008 P;;US 2665008 P;;US 2848108 P;;US 4637908 P,2007-04-18,Materials systems and methods for optoelectronic devices,"A photodetector is described along with corresponding materials, systems, and methods. The photodetector comprises an integrated circuit and at least two optically sensitive layers. A first optically sensitive layer is ovei at least a poition of the integrated circuit, and a second optically sensitive layer is over the fust optically sensitive layer Each optically sensitive layer is interposed between two electrodes. The two electrodes include a respective first electrode and a respective second electrode The integrated circuit selectively applies a bias to the electrodes and reads signals from the optically sensitive layers The signal is related to the number of photons received by the respective optically sensitive layer.",INVISAGE TECHNOLOGIES INC,HARTLEY SARGENT EDWARD;;DUKENFIELD KLEM ETHAN JACOB;;DELEHANTY MACNEIL DEAN;;MARTIN SNELGROVE WILLIAM;;GEZA PATTANTYUS-ABRAHAM ANDRAS;;GERASIMOS KONSTANTATOS;;PAUL CLIFFORD JASON;;JIANG TANG;;WILLIAM JOHNSTON KEITH;;LARISSA LEVINA;;O'REILLY HINDS SEAN;;GLEN FIFE KEITH;;ARTHUR AGHAJANIAN;;CHARLES BRADING MICHAEL;;RENE DELLA NAVE PIERRE HENRI;;MILTON DONG;;KEVIN HUNTER;;CONSTANTIN IVANOV IGOR;;YOUNG LEE JEES JAN;;DAVID OLIVER STEVEN;;HUI TIAN;;STUART ADAMS IAN;;SJOERD HOOGLAND;;ARMIN FISCHER;;RAYMOND CHIK,,https://lens.org/122-904-787-256-638,Patent Application,no,0,58,52,54,0,H01L27/14601;;H01L27/14603;;H01L27/14609;;H01L27/14647;;H01L27/14652;;H01L27/14687;;H01L27/14692;;H01L31/036;;H01L27/14641;;H01L31/1013;;G06V40/1318;;H01L27/14601;;H01L27/14603;;H01L27/14609;;H01L27/14647;;H01L27/14652;;H01L27/14687;;H01L27/14692;;H01L31/036;;H01L27/14641;;H01L31/1013,H01L27/14,,0,0,,,,ACTIVE
